Surrozen, Inc. (SRZN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Surrozen, Inc. (SRZN) closed at USD 23.75 on 2026-10-14, a change of +73 % over the past year, with a market capitalization of USD 294.66M.

Surrozen, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Surrozen, Inc. key figures

Previous close

USD 23.75 (2026-10-14)

1-year change

+73 %

Market cap

USD 294.66M

Enterprise value

USD 198.94M

P/E ratio (trailing)

-0.64

P/E ratio (forward)

-5.99

EPS (trailing)

-39.48

EPS (forward)

-4.19

PEG ratio

n/a

Price to book

-1.35

Revenue growth

408.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.53

Employees

44

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Surrozen, Inc.

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Surrozen, Inc. and compare it with other stocks.